Literature DB >> 21361732

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

Jyh-Chin Yang1, Hong-Long Wang, Herng-Der Chern, Chia-Tung Shun, Bor-Ru Lin, Chun-Jung Lin, Teh-Hong Wang.   

Abstract

STUDY
OBJECTIVE: To determine the factors that may influence Helicobacter pylori eradication in patients receiving omeprazole-amoxicillin dual therapy.
DESIGN: Prospective, randomized study.
SETTING: University-affiliated hospital in Taiwan. PATIENTS: A total of 128 adults (age range 20-75 yrs) with H. pylori-positive duodenal ulcer were enrolled; 121 completed the final evaluation. INTERVENTION: Patients were randomly assigned to one of four omeprazole-amoxicillin treatment groups, with each treatment administered for 2 weeks: O2A2 group (33 patients)--omeprazole 20 mg twice/day plus amoxicillin 500 mg 4 times/day; O2A1 group (32 patients)--omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day; O1A2 group (32 patients)--omeprazole 20 mg once/day plus amoxicillin 500 mg 4 times/day; and O1A1 group (31 patients)--omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day.
MEASUREMENTS AND MAIN RESULTS: Data were collected on H. pylori status, histologic parameters, antibiotic resistance, intragastric pH, cytochrome P450 (CYP) 2C19 genotype, and adverse reactions. The intent-to-treat cure rates (95% confidence interval [CI]) in groups O2A2, O2A1, O1A2, and O1A1 were 76% (95% CI 59-87%), 72% (95% CI 54-84%), 50% (95% CI 34-66%) and 52% (95% CI 35-68%), respectively. Eradication of H. pylori infection was statistically significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H. pylori density. All CYP2C19 poor metabolizers were cured, whereas the H. pylori cure rate in CYP2C19 extensive metabolizers varied from 44-76% in the different treatment groups. Eradication of H. pylori was favored in the omeprazole higher dose groups versus the lower dose groups (79% vs 53%, p=0.004). No secondary antibiotic resistance was found. Thirty-seven (95%) of 39 patients who failed with the initial treatment were cured by subsequent antibiotic susceptibility-driven proton pump inhibitor-based triple therapy.
CONCLUSION: Provided a maintenance dose of amoxicillin is given every 6 hours, eradication of H. pylori infection was significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H. pylori density.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21361732     DOI: 10.1592/phco.31.3.227

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  19 in total

Review 1.  Eradication of Helicobacter pylori Infection.

Authors:  Elizabeth A Marcus; George Sachs; David R Scott
Journal:  Curr Gastroenterol Rep       Date:  2016-07

2.  Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.

Authors:  Bei Tan; Jyh-Chin Yang; Carol L Young; Shrinivas Bishu; Stephanie Y Owyang; Mohamad El-Zaatari; Min Zhang; Helmut Grasberger; Jia-Ming Qian; John Y Kao
Journal:  Dig Dis Sci       Date:  2017-12-20       Impact factor: 3.199

3.  High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

Authors:  Jyh-Chin Yang; Chun-Jung Lin; Hong-Long Wang; Jin-De Chen; John Y Kao; Chia-Tung Shun; Chien-Wei Lu; Bor-Ru Lin; Ming-Jium Shieh; Ming-Chu Chang; Yu-Ting Chang; Shu-Chen Wei; Lin-Chih Lin; Wen-Chun Yeh; Jen-Shin Kuo; Chien-Chih Tung; Yew-Loong Leong; Teh-Hong Wang; Jau-Min Wong
Journal:  Clin Gastroenterol Hepatol       Date:  2014-11-14       Impact factor: 11.382

Review 4.  CYP2C19 polymorphism influences Helicobacter pylori eradication.

Authors:  Chao-Hung Kuo; Chien-Yu Lu; Hsiang-Yao Shih; Chung-Jung Liu; Meng-Chieh Wu; Huang-Ming Hu; Wen-Hung Hsu; Fang-Jung Yu; Deng-Chyang Wu; Fu-Chen Kuo
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

5.  Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.

Authors:  Hiroshi Matsumoto; Akiko Shiotani; Ryo Katsumata; Minoru Fujita; Rui Nakato; Takahisa Murao; Manabu Ishii; Tomoari Kamada; Ken Haruma; David Y Graham
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

6.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

Authors:  E A Marcus; N Inatomi; G T Nagami; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2012-09-25       Impact factor: 8.171

7.  Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.

Authors:  E A Marcus; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2015-08-04       Impact factor: 8.171

Review 8.  Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

10.  The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012.

Authors:  Chao-Hung Kuo; Fu-Chen Kuo; Huang-Ming Hu; Chung-Jung Liu; Sophie S W Wang; Yen-Hsu Chen; Ming-Chia Hsieh; Ming-Feng Hou; Deng-Chyang Wu
Journal:  Gastroenterol Res Pract       Date:  2012-06-27       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.